Corona Remedies Limited · NSE:CORONA
Corona Remedies — Q2 FY27 Earnings Presentation
36 slides from Corona Remedies's earnings presentation, Oct 30, 2026
Slide 1: Cover letter to stock exchanges: presentation to analysts/investors
October 30, 2026 To, To, Listing Operation Department Listing Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Bandra Kurla Dalal Street, Mumbai-400001 Complex, Bandra (East), Mumbai-400051 (Scrip Code: 544644) (SYMBO
Slide 2: CORONA Remedies Limited Investor Presentation: October 2026
CORONA Remedies Limited Investor Presentation: October 2026
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by CORONA Remedies Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any secur
Slide 4: Contents
Contents Operational & Financial Performance Financial & Operational Performance for Q2 and H1 FY27 About us Overview of CORONA CORONA: Outpacing IPM Growth CORONA vs. IPM Focused Brand Building Approach Strong brand recall across Therapeutic Areas Road Ahead Key Growth Strategies Annexures Manageme
Slide 5: Key Highlights for Q2 & H1 FY27
Key Highlights for Q2 & H1 FY27 Financial Highlights Return Ratios Key Highlights Q2FY27 (Y-o-Y) H1 FY27 (Y-o-Y) H1 FY27 India business contributed 97.1% of total revenue in H1 FY27. INR 441.2 Cr INR 863.6 Cr 49.8% Chronic and sub-chronic therapies R E V EN U E contribute ~72.1% in H1 FY27. + 22
Slide 6: Q2 & H1FY27 Consolidated Profit & Loss Statement
Q2 & H1FY27 Consolidated Profit & Loss Statement Profit and Loss (INR Crores) Q2FY27 Q2FY26 Y-o-Y H1FY27 H1FY26 Y-o-Y Revenue from Operations 441.2 361.1 22.2% 863.6 707.7 22.0% Gross Margin (%) 81.8% 81.0% 81.7% 81.0% Employee Cost 124.2 103.0 246.3 200.4 Other Expenses 140.5 111.0 270.2 224.6 EBIT
Slide 7: Consolidated Balance Sheet
Consolidated Balance Sheet Assets (INR Crores) Sep-26 Mar-26 Equity & Liabilities (INR Crores) Sep-26 Mar-26 Non - Current Assets 773.1 856.8 Total Equity 805.1 746.9 Property, plant and equipment 425.2 291.1 Share Capital 61.2 61.2 Capital work-in-progress 21.8 143.1 Other Equity 744.0 685.7 Intang
Slide 8: Consolidated Abridged Cash Flow Statement
Consolidated Abridged Cash Flow Statement Particulars (INR Crores) H1FY27 H1FY26 Profit Before Tax 161.1 130.5 Adjustments for: Non - Cash Items / Other Investment or Financial Items 33.7 23.3 Operating profit before working capital changes 194.8 153.8 Changes in working capital -48.6 -17.7 Cash gen
Slide 9: Contents
Contents About us Overview of CORONA CORONA: Outpacing IPM Growth CORONA vs. IPM Focused Brand Building Approach Strong brand recall across Therapeutic Areas Road Ahead Key Growth Strategies Operational & Financial Performance Financial & Operational Performance for Q2 and H1 FY27 Annexures Manageme
Slide 10: CORONA's 3C Philosophy
CORONA’s 3C Philosophy Culture • Ruthless Execution • Internal Promotion • Adaptability • Humbleness Courage CORONA’s • Accepting Mistakes 3C and improving • Robust Inorganic Philosophy Opportunities Commitment • Global Quality Products • Value Creation for Stakeholders • Long Term Sustainable Growt
Slide 11: Journey over the years
Journey over the years In -licensing Acquisition of 7 brands arrangement with from Bayer Zydus Pharma Ferring Pharmaceuticals Ltd Private Limited to Listing on NSE & BSE in market certain products December 2025 Launch of 1st under women’s health Received EAEU GMP Founded in 2004 cardiologi
Slide 12: CORONA Remedies at a Glance
CORONA Remedies at a Glance 97.1% 72.1% Jumped 6 ranks Revenue from India Business Chronic portfolio in 3 years contribution Over MAT Sep-23 to for H1FY27 for H1FY27 MAT Sep-26 EU-GMP, EAEU-GMP, #5 in Women’s Healthcare ANVISA-GMP & 81 Brands with #5 in Pain Management WHO-GMP approved Gujarat facil
Slide 13: CORONA's Competitive Edge Lies in Execution Excellence
CORONA’s Competitive Edge Lies in Execution Excellence India Focused Pharmaceutical Company Revenue from India Business contributes 97.1 % in H1FY27 and Climbed 6 Ranks in 3 Years* Market Share Gains & New Launches Consistently delivering volume growth with market share gain, new product launches, g
Slide 14: Quality Focused State of the Art Manufacturing Facilities
Quality Focused State of the Art Manufacturing Facilities Gujarat Himachal Pradesh Total Installed Capacity Installed capacity of ~1.25 Installed capacity of ~403 Mn Bn* tablets/capsules & 20 Formulations* tablets/capsules & 10 Mn liquid Mn sachets bottles Certified by EU-GMP, EAEU, 1.84 Bn units p.
Slide 15: Contents
Contents About us Overview of CORONA CORONA: Outpacing IPM Growth CORONA vs. IPM Focused Brand Building Approach Strong brand recall across Therapeutic Areas Road Ahead Key Growth Strategies Operational & Financial Performance Financial & Operational Performance for Q2 and H1 FY27 Annexures Manageme
Slide 16: Indian Pharmaceutical Market: High-Growth Landscape
Indian Pharmaceutical Market: High-Growth Landscape IPM is poised to grow at CAGR of 8-9% till FY30 Growth drivers for domestic formulations industry INR Trillion 3.1 2.3 Improving life expectancy and changing 2.1 1.8 1.9 demographic profile 1.5 1.5 01 Rising prevalence of chronic diseases FY20 FY21
Slide 17: CORONA Remedies: Consistently outperforming IPM
CORONA Remedies: Consistently outperforming IPM Sector Segment Overall IPM Vs CORONA Chronic IPM Vs CORONA IPM CORONA 1.9x 1.9x Q2FY27 22.5% 29.0% (Quarter) 12.0% 14.9% IPM CORONA 2.1x 1.8x MAT Sep-23 to 16.9% 19.6% MAT Sep-26 (3 years) 8.1% 10.6% Source: PharmaTrac – Q2 FY27, MAT Sep-23 to MAT Sep-
Slide 18: CORONA Remedies: Consistently outperforming IPM
CORONA Remedies: Consistently outperforming IPM Consistently outperforming IPM in all metrics across timeframes Volume Price New Introduction Total Revenue IPM CORONA 2.9x 1.5x 1.9x 1.9x Q2FY27 (Quarter) 6.5% 8.9% 7.0% 22.5% 6.1% 3.6% 12.0% 2.3% IPM CORONA 3.3x 1.2x 2.2x 2.1x MAT Sep-23 to MAT Sep-2
Slide 19: Consistently cementing position with focus on four Key Therapies
Consistently cementing position in segment with focus on four Key Therapies Women’s Healthcare Cardio-Diabeto Pain Management Urology 2.0x 1.8x 3.4x 3.1x CORONA Remedies vs. IPM 14.5% 22.0% 27.7% 42.8% MAT Sep-23 to MAT Sep-26 7.1% 12.0% 8.2% 13.7% IPM CORONA IPM CORONA IPM CORONA IPM CORONA Women’s
Slide 20: Focussed presence in the Middle of the Pyramid segment
Focussed presence in the “Middle of the Pyramid’’ segment Specialty-wise prescription split IPM 8% Super 12% Strategic focus on Specialist specialist and super- specialist doctors in the ‘middle of the pyramid’; resulting in a higher prescription contribution compared with IPM 35% 35% Specialist 55%
Slide 21: Contents
Contents About us Overview of CORONA CORONA: Outpacing IPM Growth CORONA vs. IPM Focused Brand Building Approach Strong brand recall across Therapeutic Areas Road Ahead Key Growth Strategies Operational & Financial Performance Financial & Operational Performance for Q2 and H1 FY27 Annexures Manageme
Slide 22: Engine Brands approach with Successful Scaling Up of Brands
“Engine” Brands approach with Successful Scaling Up of Brands 33 Engine Brands Established track record of building and scaling brands Brands with Sales ~79% 29 >INR 10 Crs 38 Contribution to Domestic Sales 1st 200 cr MAT Sep-26 1 brand 3 ~22% 7 CAGR over 1 MAT Sep-23 to MAT Sep-26 No. of Brands 10
Slide 23: Acquisition & Strategic Collaborations for India Business
Acquisition & Strategic Collaborations for India Business Significantly scaled-up acquired brands Strategic collaborations for India Business Sr. No Acquired From Brands GSK Pharmaceuticals Limited Dilo Ferring Pharmaceuticals, Switzerland 1 Stelbid In-Licensing Arrangement for certain products in G
Slide 24: Strategic Portfolio Diversification & Brand Development
Strategic Portfolio Diversification & Brand Development Chronic v/s Acute 28.1% Chronic FY16 45.3% Acute Accelerating growth in 54.7% FY26 chronic therapies - 71.9% Outperforming the IPM Womens Healthcare 23.7% Pain Management Therapy Wise 27.5% 32.8% Cardio Diabeto Strengthening focus on core FY16
Slide 25: Contents
Contents About us Overview of CORONA CORONA: Outpacing IPM Growth CORONA vs. IPM Focused Brand Building Approach Strong brand recall across Therapeutic Areas Road Ahead Key Growth Strategies Operational & Financial Performance Financial & Operational Performance for Q1 and H1 FY27 Annexures Manageme
Slide 26: Future Growth Strategies
CORONA Remedies Limited Future Growth Strategies • Improve MR productivity, expanding prescriber base and increasing the number of products Increase market share 1 within the domestic IPM prescribed per prescriber • Intensify engagement with super-specialist prescribers in metro, semi-metro, and urb
Slide 27: Contents
Contents About us Overview of CORONA CORONA: Outpacing IPM Growth CORONA vs. IPM Focused Brand Building Approach Strong brand recall across Therapeutic Areas Road Ahead Key Growth Strategies Operational & Financial Performance Financial & Operational Performance for Q1 and H1 FY27 Annexures Manageme
Slide 28: Professional Senior Management Leading the Way
Professional Senior Management Leading the Way Niravkumar Kritikumar Mehta Ankur Kritikumar Mehta Viral Bhupendrabhai Sitwala Managing Director & CEO Joint Managing Director Whole-Time Director Over 2 decades of experience in the Over 2 decades of experience in the Over 2 decades of experience in th
Slide 29: Experienced Board of Directors
Experienced Board of Directors Niravkumar Kritikumar Mehta Ankur Kritikumar Mehta Viral Bhupendrabhai Sitwala Dr. Kiritkumar Laxmidas Mehta Managing Director & CEO Joint Managing Director Whole-Time Director Chairman and Non-Executive Director Ameetkumar Hiranyakumar Desai Monica Kanuga Shirish Gund
Slide 30: ESG @ CORONA Remedies
ESG @ CORONA Remedies • Existing solar power plant of 1.3 MW at Bhayla Plant and 4.25 MW in Solar Park Spread across 11.9 E Acres which saves significant electricity cost • Protection of Environment by Tree Plantation, Distribution of Plant Saplings, initiatives like wearing un-ironed clothes • Effl
Slide 31: Historical Consolidated Profit & Loss Statement
Historical Consolidated Profit & Loss Statement Profit and Loss (₹ Crores) FY26 FY25 FY24 FY23 Revenue from Operations 1,403.2 1,196.4 1,014.5 884.1 Cost of Goods Sold 260.9 236.5 226.8 211.0 Gross Profit 1,142.2 959.9 787.6 673.1 Gross Margin (%) 81.4% 80.2% 77.6% 76.1% Employee Cost 403.0 346.1 29
Slide 32: Historical Consolidated Balance Sheet
Historical Consolidated Balance Sheet Assets (₹ Crores) Mar-26 Mar-25 Mar-24 Mar-23 Equity & Liabilities (₹ Crores) Mar-26 Mar-25 Mar-24 Mar-23 Non - Current Assets 856.8 591.0 540.7 303.5 Total Equity 746.9 606.3 480.4 408.5 Property, plant and equipment 291.1 198.7 191.0 184.1 Share Capital 61.2 6
Slide 33: Historical Consolidated Abridged Cash Flow Statement
Historical Consolidated Abridged Cash Flow Statement Abridged Cash Flow Statement (₹ Crores) FY26 FY25 FY24 FY23 Net Profit Before Tax 240.4 198.5 118.5 110.9 Adjustments for: Non - Cash Items / Other Investment or Financial Items 44.4 52.3 46.9 22.6 Operating profit before working capital changes 2
Slide 34: Historical Financial Statement
Historical Financial Statement Revenue (₹ Crores) EBITDA (₹ Crores) PAT (₹ Crores) 1,403.2 293.4 199.4 17% 1,196.4 +32% 240.0 +33% 1,014.5 149.4 884.1 154.7 128.0 90.5 84.9 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26* *Excludes onetime statutory impact of New Labor Code Rs.19.1 Cr (P
Slide 35: Historical Financial Ratios
Historical Financial Ratios ROCE (%) ROE (%) 41.3% 40.8% 29.2% 27.5% 31.2% 23.3% 28.4% 20.4% FY23 FY24 FY25 FY26* FY23 FY24 FY25 FY26* OCF/EBITDA (%) Net working Capital Days 101.3% 31 27 80.2% 79.4% 78.2% 23 24 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 *ROE and ROCE for FY26 is annualised & Excludes
Slide 36: THANK YOU
THANK YOU For further information, please contact: CORONA Remedies Limited Strategic Growth Advisors Private Limited (SGA) CIN: L24231GJ2004PLC044656 CIN: U74140MH2010PTC204285 Ms. Chetna Dharajiya – Company Secretary & Compliance Officer Mr. Sagar Shroff / Mr. Tanay Shah [email protected] / ta